Talanta, Journal Year: 2024, Volume and Issue: 285, P. 127262 - 127262
Published: Nov. 22, 2024
Language: Английский
Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)
Published: Nov. 14, 2024
RNA therapeutics, such as mRNA, siRNA, and CRISPR–Cas9, present exciting avenues for treating diverse diseases. However, their potential is commonly hindered by vulnerability to degradation poor cellular uptake, requiring effective delivery systems. Lipid nanoparticles (LNPs) have emerged a leading choice in vivo delivery, offering protection against degradation, enhanced facilitation of endosomal escape. LNPs encounter numerous challenges targeted vivo, demanding advanced particle engineering, surface functionalization with targeting ligands, profound comprehension the biological milieu which they function. This review explores structural physicochemical characteristics LNPs, in-vivo fate, customization therapeutics. We highlight quality-by-design (QbD) approach beyond liver, focusing on biodistribution, immunogenicity, toxicity. In addition, we explored current strategies associated ensuring repeated-dose efficacy, safety, tissue-specific gene delivery. Furthermore, provide insights into clinical applications various classes diseases finally prospects
Language: Английский
Citations
9
ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 14, 2025
Conjugation of serum albumin protein with catechol-containing dopamine molecules provides an alternative method for the preparation nanoparticles (NPs). A commonly used desolvation utilizes glutaraldehyde as a cross-linking agent. Here, catechol mechanism is instead providing advantages to prevent toxicity and undesirable reaction cargo molecules. Covalent between conjugated bovine (D-BSA) proteins was obtained in presence sodium periodate (NaIO4) oxidizer. As result, spherical D-BSA NPs uniform size distribution around 100 nm diameter negative zeta potential −28 mV were prepared. Optimal conditions reached when dopamine:IO4– molar ratio 2:1, pH 7.4 medium, acetone desolvating agent used. Furthermore, display antioxidant properties, have rapid biodegradability trypsin, high doxorubicin (DOX) loading (9.1%) sustainable drug release. DOX loaded also caused up 90% breast cancer cell (MCF-7) death within 24 h. These results show that carrying can alternatively be prepared via covalently cross-linked groups delivery studies.
Language: Английский
Citations
1
International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 4235 - 4255
Published: April 1, 2025
α-Solanine (α-Sol) shows promise for pancreatic cancer (PC) treatment by inhibiting PC cell proliferation, migration, and invasion. However, its clinical application is hindered poor tumor targeting, significant toxicity, undesirable pharmacokinetics. To address these issues, this study developed a nanoparticle delivery system (PBSO NPs) using bovine serum albumin as carrier, with polyallylamine hydrochloride surface modification to enhance α-Sol delivery. PBSO NPs were characterized transmission electron microscopy, dynamic light scattering, size analyzers, Fourier-transform infrared spectroscopy. Their in vitro drug release profile cellular uptake capabilities evaluated. Furthermore, experiments conducted mouse cells (Panc02) investigate the effects of on Panc02 viability, invasion, apoptosis. Additionally, xenograft model was established vivo explore impact growth. This successfully favorable morphology physiological stability, capable enhancing uptake. In demonstrated that significantly inhibited invasion while promoting Moreover, enhanced inhibitory cells. further confirmed improved therapeutic efficacy against partially reducing toxicity. exhibited good biocompatibility. apoptosis, thereby suppressing progression PC. provides promising strategy treatment.
Language: Английский
Citations
1
Advanced Science, Journal Year: 2025, Volume and Issue: unknown
Published: May 8, 2025
Abstract Nanodrug delivery systems (NDDS) have demonstrated broad application prospects in disease treatment, prevention, and diagnosis due to several advantages, including functionalization capability, high drug‐loading capacity, drug stability protection, the enhanced permeability retention (EPR) effect. However, their clinical translation still faces multiple challenges, rapid clearance by reticuloendothelial system (RES), poor targeting specificity, insufficient efficiency crossing biological barriers. To address these limitations, researchers developed carrier‐mediated nanomedicine hitchhiking strategy (BCM‐NHS), which leverages circulating cells, proteins, or bacteria as natural “mobile carriers” enhance delivery. This approach enables nanocarriers inherit intrinsic properties, endowing them with immune evasion, prolonged circulation, dynamic targeting, biocompatibility, biodegradability, naturally optimized interfaces. Here, a systematic overview of BCM‐NHS is provided. First, review delves into methods nanoparticles (NPs) binding immobilization, encompassing both surface‐attachment‐mediated “backpack” encapsulation‐based “Trojan horse” strategy. Second, classification carriers, cell‐based non‐cell‐based elucidated. Third, physical properties release mechanisms nanomaterials are thoroughly described. Finally, latest applications therapeutic diagnostic contexts across various models tumor, ischemic stroke, pneumonia highlighted.
Language: Английский
Citations
1
Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 179, P. 117323 - 117323
Published: Aug. 28, 2024
Recently, increased attention has been focused on the regulatory mechanism and potential clinical application of ferroptosis in cancer cells, especially therapy-related ferroptosis. However, treatment-related prospects strategies for future treatment still require further clarification. This review highlights molecular relationships between different antitumour drugs, including commonly used chemotherapy radiation therapy vitamins, also proposes treatments that involve ferroptosis, with an aim to develop a new strategy transformative emerging field improve therapy.
Language: Английский
Citations
4
International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: unknown, P. 125049 - 125049
Published: Dec. 1, 2024
Language: Английский
Citations
3
Journal of Controlled Release, Journal Year: 2025, Volume and Issue: 381, P. 113562 - 113562
Published: Feb. 22, 2025
Language: Английский
Citations
0
Langmuir, Journal Year: 2025, Volume and Issue: unknown
Published: March 7, 2025
Therapeutic proteins play a crucial role in modern healthcare. However, the rapid clearance of circulation system poses significant threat to their therapeutic efficacy. The generation anti-drug antibodies expedites drug clearance, resulting another challenge overcome protein delivery. Several methods increase half-lives these and minimize immunogenicity have been developed. This Review discusses causes body, evaluates FDA-approved strategies prolong circulation, highlights recent progress field. Additionally, strengths drawbacks our perspectives for advancing delivery are provided.
Language: Английский
Citations
0
International Journal of Nanomedicine, Journal Year: 2025, Volume and Issue: Volume 20, P. 3493 - 3525
Published: March 1, 2025
Human serum albumin (HSA) has emerged as a promising carrier for nanodrug delivery, offering unique structural properties that can be engineered to overcome key challenges in cancer treatment, especially resistance chemotherapy. This review focuses on the cellular uptake of albumin-based nanoparticles and modifications enhance their ability bypass mechanisms, particularly multidrug type 1 (MDR1), by improving targeting cells. In our approach, we integrate chemical albumin, its interactions with cells, surface delivery systems enable those related MDR1, precisely target receptors cells improve treatment efficacy. We discuss while well-established such gp60 gp18/30 are crucial transcytosis, biology remains underexplored, limiting translational potential. Additionally, explore potential emerging targets, cluster differentiation 44 (CD44), (CD36) transferrin receptor TfR1, well advantages using dimeric forms (dHSA) further resistant Drawing from clinical examples, including success albumin-bound paclitaxel (Abraxane) new formulations like Pazenir Fyarro (for Sirolimus), identify gaps current knowledge propose strategies optimize systems. conclusion, nanoparticles, when tailored appropriate modifications, have By enhancing albumin's efficiently deliver therapeutic agents, these carriers represent approach addressing one oncology's most persistent challenges, substantial outcomes.
Language: Английский
Citations
0
ACS Applied Bio Materials, Journal Year: 2025, Volume and Issue: unknown
Published: March 25, 2025
Chemodynamic therapy (CDT), which utilizes transition metal ions to catalyze Fenton-like reactions for the eradication of tumor cells, has attracted substantial attention in field nanocatalysis. However, therapeutic efficacy CDT as a monotherapy is often limited by an insufficient level hydrogen peroxide (H2O2) and overexpressed glutathione (GSH) within cells. Because high copper content tissues, ionophore was strategically employed enhance intracellular accumulation copper, thereby potentiating effect. Additionally, bovine serum albumin (BSA) used modify ionophore, naphthazarin (Nap), promote its targeting cells ensure biosafety. The BSA-coated Nap nanoparticles, could recruit Cu2+ situ, were further deposited onto surface manganese carbonate nanocube (Nap-BM NPs). synergistic action accelerated decomposition H2O2 into hydroxyl radicals (•OH) consumed GSH, leading cellular mortality via mitochondrial pathways. With low cytotoxicity good biocompatibility normal developed Nap-BM NPs significantly enhanced outcomes leveraging multiple reaction mechanisms augment CDT, offering promising potential clinical applications contributing valuable insights field.
Language: Английский
Citations
0